Switch theme
Sign up to access all valuation multiples
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.
1947
3.6K+
LTM Revenue $3.4B
LTM EBITDA $784M
$4.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ono Pharmaceutical has a last 12-month revenue (LTM) of $3.4B and a last 12-month EBITDA of $784M.
In the most recent fiscal year, Ono Pharmaceutical achieved revenue of $3.4B and an EBITDA of $1.2B.
Ono Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ono Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| Gross Profit | $2.5B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $784M | XXX | $1.2B | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $750M | XXX | $1.1B | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $594M | XXX | $878M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ono Pharmaceutical's stock price is JPY 1565 (or $11).
Ono Pharmaceutical has current market cap of JPY 735B (or $5.0B), and EV of JPY 672B (or $4.6B).
See Ono Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6B | $5.0B | XXX | XXX | XXX | XXX | $0.77 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ono Pharmaceutical has market cap of $5.0B and EV of $4.6B.
Ono Pharmaceutical's trades at 1.4x EV/Revenue multiple, and 3.8x EV/EBITDA.
Equity research analysts estimate Ono Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ono Pharmaceutical has a P/E ratio of 8.5x.
See valuation multiples for Ono Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV (current) | $4.6B | XXX | $4.6B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 5.9x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBIT | 6.1x | XXX | 4.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.5x | XXX | 5.9x | XXX | XXX | XXX |
| EV/FCF | 8.2x | XXX | 6.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOno Pharmaceutical's last 12 month revenue growth is 2%
Ono Pharmaceutical's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.4M for the same period.
Ono Pharmaceutical's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ono Pharmaceutical's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ono Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | -16% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ono Pharmaceutical acquired XXX companies to date.
Last acquisition by Ono Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Ono Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ono Pharmaceutical founded? | Ono Pharmaceutical was founded in 1947. |
| Where is Ono Pharmaceutical headquartered? | Ono Pharmaceutical is headquartered in Japan. |
| How many employees does Ono Pharmaceutical have? | As of today, Ono Pharmaceutical has 3.6K+ employees. |
| Who is the CEO of Ono Pharmaceutical? | Ono Pharmaceutical's CEO is Mr. Gyo Sagara. |
| Is Ono Pharmaceutical publicy listed? | Yes, Ono Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Ono Pharmaceutical? | Ono Pharmaceutical trades under 4528 ticker. |
| When did Ono Pharmaceutical go public? | Ono Pharmaceutical went public in 1963. |
| Who are competitors of Ono Pharmaceutical? | Similar companies to Ono Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Ono Pharmaceutical? | Ono Pharmaceutical's current market cap is $5.0B |
| What is the current revenue of Ono Pharmaceutical? | Ono Pharmaceutical's last 12 months revenue is $3.4B. |
| What is the current revenue growth of Ono Pharmaceutical? | Ono Pharmaceutical revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Ono Pharmaceutical? | Current revenue multiple of Ono Pharmaceutical is 1.4x. |
| Is Ono Pharmaceutical profitable? | Yes, Ono Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ono Pharmaceutical? | Ono Pharmaceutical's last 12 months EBITDA is $784M. |
| What is Ono Pharmaceutical's EBITDA margin? | Ono Pharmaceutical's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Ono Pharmaceutical? | Current EBITDA multiple of Ono Pharmaceutical is 5.9x. |
| What is the current FCF of Ono Pharmaceutical? | Ono Pharmaceutical's last 12 months FCF is $564M. |
| What is Ono Pharmaceutical's FCF margin? | Ono Pharmaceutical's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Ono Pharmaceutical? | Current FCF multiple of Ono Pharmaceutical is 8.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
